Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics

12.4BUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US05464T1043
CUSIP
05464T104
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
1.06
Dividend Share
-
Dividend Yield
-
Earnings Share
-3.71
Wall Street Target Price
282.51
EPS Estimate Current Year
-1.73
EPS Estimate Next Year
5.85
EPS Estimate Current Quarter
-0.8617
EPS Estimate Next Quarter
-0.665
Most Recent Quarter
-
Revenue TTM
708,236,032
Gross Profit TTM
655,822,016
EBITDA
-167,234,000
Profit Margin
-26.59%
Return On Assets TTM
-16.84%
Return On Equity TTM
-349.38%
Revenue Per Share TTM
14.072
Qtly Revenue Growth YOY
57.40%
Diluted Eps TTM
-3.71
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
333
Price Sales TTM
17.5108
Price Book MRQ
227.1934
Enterprise Value Revenue
17
Enterprise Value EBITDA
-14
290.59
4.74%191.00
1.04%661.71
0.91%139.01
0.71%480.12
0.64%272.08
0.16%865.00
0.00%81.96
0.00%910.95
-0.90%20.00
-0.79%
See which Billionaires own this investment
Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics
Monday morning #earnings https://t.co/lObOE0dgsr $TTD $BNTX $WKHS $GOLD $TSN $BRK.B (really tomorrow morning) $VTRS $DISH $PRPL $CRNC $BHVN $BFLY $XPEL $BALY $AGEN $ELAN $ENR $USFD $KNDI $SWAV $KOS $VRTV $TGNA $APD $AVYA $CEVA $ITCI $GTES $RDNT $AMRX $MPAA $KLR $SGMS $AXSM https://t.co/Ln7SrRCAJd